Teachers Retirement System of The State of Kentucky Buys Shares of 177,196 Denali Therapeutics Inc. (NASDAQ:DNLI)

Teachers Retirement System of The State of Kentucky bought a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Rating) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 177,196 shares of the company’s stock, valued at approximately $5,438,000.

A number of other institutional investors and hedge funds have also bought and sold shares of DNLI. China Universal Asset Management Co. Ltd. bought a new stake in Denali Therapeutics during the 3rd quarter valued at $35,000. Allspring Global Investments Holdings LLC raised its position in Denali Therapeutics by 43.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,313 shares of the company’s stock valued at $101,000 after purchasing an additional 1,005 shares in the last quarter. Quantbot Technologies LP raised its position in Denali Therapeutics by 362.5% during the 3rd quarter. Quantbot Technologies LP now owns 3,700 shares of the company’s stock valued at $113,000 after purchasing an additional 2,900 shares in the last quarter. Virtus ETF Advisers LLC raised its position in shares of Denali Therapeutics by 41.0% in the 2nd quarter. Virtus ETF Advisers LLC now owns 4,839 shares of the company’s stock worth $142,000 after acquiring an additional 1,406 shares in the last quarter. Finally, Great West Life Assurance Co. Can bought a new position in shares of Denali Therapeutics in the 3rd quarter worth $142,000. 67.26% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. SVB Securities assumed coverage on Denali Therapeutics in a research report on Monday, January 30th. They issued an “outperform” rating and a $50.00 price target for the company. Cowen assumed coverage on Denali Therapeutics in a research report on Monday, December 5th. They issued an “outperform” rating for the company. Morgan Stanley reduced their price target on Denali Therapeutics from $65.00 to $61.00 and set an “overweight” rating for the company in a research report on Wednesday, March 1st. SVB Leerink reissued an “outperform” rating and issued a $50.00 price target on shares of Denali Therapeutics in a research report on Monday, January 30th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $105.00 target price on shares of Denali Therapeutics in a research report on Thursday, February 23rd. Thirteen investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $54.58.

Denali Therapeutics Stock Performance

Denali Therapeutics stock opened at $23.33 on Friday. The business’s 50-day simple moving average is $28.45 and its two-hundred day simple moving average is $29.14. The company has a market cap of $3.19 billion, a PE ratio of -8.97 and a beta of 1.39. Denali Therapeutics Inc. has a fifty-two week low of $20.24 and a fifty-two week high of $39.43.

Denali Therapeutics (NASDAQ:DNLI – Get Rating) last posted its quarterly earnings results on Monday, February 27th. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.02. Denali Therapeutics had a negative return on equity of 35.67% and a negative net margin of 300.55%. The business had revenue of $10.28 million for the quarter, compared to the consensus estimate of $11.29 million. During the same quarter in the previous year, the business earned ($0.62) EPS. The company’s quarterly revenue was down 17.8% compared to the same quarter last year. As a group, analysts predict that Denali Therapeutics Inc. will post -3.46 EPS for the current fiscal year.

Insider Transactions at Denali Therapeutics

In other news, insider Carole Ho sold 2,913 shares of the company’s stock in a transaction dated Wednesday, January 4th. The stock was sold at an average price of $28.69, for a total value of $83,573.97. Following the sale, the insider now owns 175,500 shares in the company, valued at $5,035,095. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Carole Ho sold 2,913 shares of the company’s stock in a transaction dated Wednesday, January 4th. The stock was sold at an average price of $28.69, for a total value of $83,573.97. Following the sale, the insider now owns 175,500 shares in the company, valued at $5,035,095. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ryan J. Watts sold 33,815 shares of the stock in a transaction that occurred on Monday, February 13th. The stock was sold at an average price of $30.08, for a total value of $1,017,155.20. Following the transaction, the chief executive officer now owns 2,239,913 shares in the company, valued at approximately $67,376,583.04. The disclosure for this sale can be found here. Insiders have sold 91,020 shares of company stock worth $2,689,975 over the last quarter. 12.70% of the stock is currently owned by insiders.

Denali Therapeutics Company Profile

(Get Rating)

Denali Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.